Evaluation of the USP Risedronate Sodium Assay

Significance of the Topic

Risedronate sodium is a first-line bisphosphonate widely employed in the prevention and treatment of osteoporosis. Accurate quantification is essential for ensuring correct dosage in both the active pharmaceutical ingredient (API) and finished tablet formulations.

Objectives and Study Overview

The objective of this study was to evaluate and validate the United States Pharmacopeia (USP) monograph ion chromatography assay for risedronate sodium. Key goals included verifying compliance with USP specifications, identifying critical chromatographic parameters, and assessing method robustness for routine quality control use.

Methodology and Instrumentation

The assay was performed on a Thermo Scientific Dionex ICS-3000 system using a Dionex IonPac AS7 analytical column (4×250 mm) with AG7 guard (4×50 mm). Chromatographic conditions included:

• Mobile phase: 4.8 mM EDTA, adjusted to pH 9.5±0.1
• Flow rate: 0.8 mL/min
• Column temperature: 25 °C
• Injection volume: 20 μL
• Detection: UV absorbance at 263 nm
• Total run time: 20 min

Main Results and Discussion

The method achieved baseline separation of risedronate and its related impurities (compounds A and C) within 15 min, with retention times of approximately 9.4, 10.2, and 11.9 min, respectively. Experimental performance compared to USP criteria:

• Tailing factor: ≤1.5 (observed ~1.3)
• Resolution: ≥2.3–2.5 (observed ~2.5–4.4)
• Peak area precision (RSD): ≤1.0% for API (0.32%) and tablets (0.19%)
• Assay accuracy: 99.6% for API and 98.3% for product
• Linearity (r²): ≥0.9999 over 0.5–1.5 mg/mL (API) and 0.05–0.15 mg/mL (tablet)
• LOD/LOQ: 0.08 μg/mL and 0.3 μg/mL
• Accuracy and precision across 75–125% levels met USP limits
• Robustness: method remained within specifications under ±2 °C temperature, ±0.1 pH variation, and across different column batches

Benefits and Practical Application of the Method

This anion-exchange assay offers a straightforward, rugged, and metal-free approach that avoids chelation challenges common in reversed-phase ion-pairing methods. It supports reliable QC release testing of both the drug substance and finished tablets.

Future Trends and Potential Applications

Potential developments include coupling with mass spectrometry for enhanced impurity profiling, miniaturization and high-throughput formats, application to other bisphosphonates or polyphosphonates, and the adoption of greener mobile-phase solvents.

Conclusion

The USP monograph ion chromatography method was successfully validated on the Dionex IonPac AS7 column with EDTA eluent. It meets or exceeds all USP specifications for specificity, precision, accuracy, linearity, and robustness, making it suitable for routine QC analysis of risedronate sodium.

Reference

1. Thermo Fisher Scientific, Inc. Dionex Application Note 289: Evaluation of the USP Risedronate Sodium Assay, LPN 2926. Sunnyvale, CA, 2011.